Prospective, Randomized, Open Label, Blinded-Endpoint Study to Compare Awakening Versus Bedtime Administration of 5-10 mg Ramipril in Terms of Systolic Blood Pressure Lowering Determined by ABPM [ambulatory blood pressure monitoring] in Subjects With Mild-to-Moderate Essential Hypertension.
Phase of Trial: Phase IV
Latest Information Update: 10 Sep 2009
At a glance
- Drugs Ramipril (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms HYCCRA
- 10 Sep 2009 Actual patient number changed from 115 to 120 as reported by ClinicalTrials.gov.
- 09 Sep 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 01 Jul 2009 Results published in Hypertension.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History